cipaglucosidase alfa miglustat
Selected indexed studies
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. (Lancet Neurol, 2021) [PMID:34800400]
- Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. (J Comp Eff Res, 2024) [PMID:39287071]
- ** (, 2023) [PMID:40163608]
_Worker-drafted node — pending editorial review._
Connections
cipaglucosidase alfa miglustat is a side effect of
Sources
- Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. (2021) pubmed
- Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data. (2024) pubmed
- PMID:40163608 (2023) pubmed
- Cipaglucosidase Alfa. (2006) pubmed
- 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). (2024) pubmed
- Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. (2024) pubmed
- Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease. (2024) pubmed
- Regulatory news: Cipaglucosidase alfa-atga (Pombiliti) coadministered with Miglustat (Opfolda) for adults with late-onset Pompe disease. (2024) pubmed
- PMID:41533825 (2025) pubmed
- Cipaglucosidase Alfa: First Approval. (2023) pubmed